Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

XRAY PEER ANALYSIS

Dentsply Sirona Inc — metric-by-metric comparison with peers and the industry median

XRAYDentsply Sirona Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Instruments & Supplies

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Medical Instruments & Supplies

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
XRAYIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
XRAY-24.0%ANN+6.3%FPH-1.9%RMD-20.8%CTEC-14.8%EL-25.2%
Year-to-Date (YTD)
XRAY+7.8%ANN-6.0%FPH+1.1%RMD-14.7%CTEC-7.9%EL-34.7%
1-Year
Split-adjusted
XRAY-24.0%LMAT+24.0%PLSE+90.3%ATRC+2.0%WRBY+31.4%STAA+53.1%
Year-to-Date (YTD)
XRAY+7.8%LMAT+28.5%PLSE+112.0%ATRC-18.1%WRBY+34.1%STAA+18.4%

Key Metric Comparison

P/E

Lower is better
XRAY—ANN24.16FPH41.27RMD20.35CTEC34.11EL34.91Median 34.91

ROE

Higher is better
XRAY-37.7%ANN7.2%FPH23.3%RMD25.2%CTEC10.9%EL5.8%Median 2.3%

Net Margin

Higher is better
XRAY-17.1%ANN6.7%FPH20.0%RMD27.4%CTEC7.2%EL8.1%Median 3.9%

Revenue Growth

Higher is better
XRAY-1.0%ANN11.4%FPH4.8%RMD10.5%CTEC6.8%EL7.5%Median 6.4%

P/E

Lower is better
XRAY—LMAT37.97PLSE—ATRC—WRBY—STAA—Median 34.91

ROE

Higher is better
XRAY-37.7%LMAT16.5%PLSE-80.7%ATRC-1.0%WRBY0.4%STAA-6.0%Median 2.3%

Net Margin

Higher is better
XRAY-17.1%LMAT24.3%PLSE-9,929.0%ATRC-0.8%WRBY0.2%STAA-7.2%Median 3.9%

Revenue Growth

Higher is better
XRAY-1.0%LMAT13.3%PLSE-69.9%ATRC15.0%WRBY12.0%STAA4.0%Median 6.4%

All Metrics

Valuation
MetricXRAYANNFPHRMDCTECELInd. Median
P/E—24.1641.2720.35●34.1134.9134.91
P/B1.771.66●9.084.733.942.082.95
EV/EBITDA—12.5223.2913.8311.98●14.0114.72
P/S0.63●1.588.275.562.452.842.79
Financial Health
MetricXRAYANNFPHRMDCTECELInd. Median
Current Ratio1.532.362.313.01●1.530.992.40
Debt/Equity176.9%46.2%6.9%●13.0%100.0%37.0%34.8%
NetDebt/EBITDA-16.86●2.10-0.39-0.382.331.661.44
Profitability
MetricXRAYANNFPHRMDCTECELInd. Median
Net Margin-17.1%6.7%20.0%27.4%●7.2%8.1%3.9%
ROE-37.7%7.2%23.3%25.2%●10.9%5.8%2.3%
ROA-11.1%4.2%17.3%18.6%●4.8%3.6%1.5%
EBITDA Margin-3.5%15.2%34.9%39.1%●25.3%23.0%13.8%
Growth + Dividend
MetricXRAYANNFPHRMDCTECELInd. Median
Rev. Growth-1.0%11.4%●4.8%10.5%6.8%7.5%6.4%
NI Growth—23.8%●-11.6%15.9%-8.0%-1.8%14.0%
Div. Yield4.3%1.7%1.6%8.0%●3.3%2.3%1.7%
Payout-20.4%53.2%53.9%22.4%78.1%0.0%22.4%
Valuation
MetricXRAYLMATPLSEATRCWRBYSTAAInd. Median
P/E—37.97————34.91
P/B1.77●5.8329.863.179.784.012.95
EV/EBITDA—22.76●—60.2467.09—14.72
P/S0.63●9.252,636.182.824.134.872.79
Financial Health
MetricXRAYLMATPLSEATRCWRBYSTAAInd. Median
Current Ratio1.5314.32●7.264.292.335.122.40
Debt/Equity176.9%46.7%10.8%15.2%63.2%10.6%●34.8%
NetDebt/EBITDA-16.86●-1.840.83-2.88-0.9430.831.44
Profitability
MetricXRAYLMATPLSEATRCWRBYSTAAInd. Median
Net Margin-17.1%24.3%●-9,929.0%-0.8%0.2%-7.2%3.9%
ROE-37.7%16.5%●-80.7%-1.0%0.4%-6.0%2.3%
ROA-11.1%10.5%●-69.4%-0.7%0.2%-4.6%1.5%
EBITDA Margin-3.5%37.6%●-9,866.7%4.5%6.1%-1.4%13.8%
Growth + Dividend
MetricXRAYLMATPLSEATRCWRBYSTAAInd. Median
Rev. Growth-1.0%13.3%-69.9%15.0%●12.0%4.0%6.4%
NI Growth—38.2%————14.0%
Div. Yield4.3%●0.9%—0.0%——1.7%
Payout-20.4%30.9%—0.0%——22.4%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on XRAY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.